Skip to main content
. Author manuscript; available in PMC: 2015 Nov 20.
Published in final edited form as: Vaccine. 2013 Apr 18;31(0 2):B122–B128. doi: 10.1016/j.vaccine.2012.10.116

Table 1.

Summary of 5 data sources and their key characteristics.

Study Published literature review Grey literature review In-depth study of 3 countries Interviews with country and regional informants Analysis of impact on DTP3 coverage
Methodology Systematic review Review Mixed methods Qualitative Quantitative
Time frame 1911 to Sept 2010 Jan 2000–Oct 2010 July 2011–Jan 2012 June 2011 1999–2009
Methodology description Search of 7 publication databases using 104terms encompassing immunization and health systems Search of 7 data sources for documents that were not peer-reviewed or published commercially Semi-structured interviews and questionnaires Semi- structured interviews Multivariate, cross-national,mixed-effect longitudinal model to evaluate new vaccine introduction on DTP3coverage
Data sources Medline, Embase, Nursing Update, West African Journal of Nursing, CINAHL, Web of Science and Global Health Popline, PubMED, Cochrane Library, ELDIS, System for Information on Grey Literature in Europe, CAB Abstracts, and WHO regional offices Guatemala – rotavirus vaccine introduction in 2010; Kenya – 10 valent pneumococcal conjugate vaccine introduction in 2011; Mali – Meningococcal A vaccine introduction in 2010/11 National immunization and health officials of WHO regional offices WHO/UNICEF Coverage Estimates
Scope 130 articles included in the analysis (of 24,767 articles identified through search terms) 61 documents included 116 interviews conducted with national, regional and district staff; 87 health facilities responded to questionnaires Interviews conducted with 9 senior country immunization programme staff and 7 WHO regional staff 152 new vaccine introductions included
Notable features 75% of articles from high-income countries; majority of studies not designed to address the research question Focus on low and middle-income countries; majority of studies not designed to address the research question Middle and low-income countries with diverse health systems; 3 different vaccines considered Mostly introduction of pentavalent DTP-hepatitis B-Haemophilus influenzae type b (Hib) or hepatitis B vaccines Many countries but primarily introduction of pentavalent DTP-hepatitis B-Hib or hepatitis B vaccines